Relenza, Dectova(zanamivir)
Dectova, Relenza (zanamivir) is a small molecule pharmaceutical. Zanamivir was first approved as Relenza on 1999-07-26. It is used to treat human influenza in the USA. It has been approved in Europe to treat human influenza.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Relenza
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Zanamivir
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| RELENZA | GSK | N-021036 RX | 1999-07-26 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| relenza | New Drug Application | 2018-06-21 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| human influenza | EFO_0007328 | D007251 | J11.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
24 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Human influenza | D007251 | EFO_0007328 | J11.1 | 5 | 5 | 5 | 1 | 4 | 19 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Arthralgia | D018771 | HP_0002829 | M25.5 | — | 1 | — | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | — | — | 1 | 1 |
| Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
| Disease progression | D018450 | — | — | — | — | 1 | 1 | ||
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | — | 1 | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | — | — | 1 | 1 |
| Otitis media | D010033 | EFO_0004992 | H66.9 | — | — | — | — | 1 | 1 |
| Bronchitis | D001991 | J40 | — | — | — | — | 1 | 1 | |
| Bronchial spasm | D001986 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ZANAMIVIR |
| INN | zanamivir |
| Description | Zanamivir is a member of guanidines. It has a role as an EC 3.2.1.18 (exo-alpha-sialidase) inhibitor and an antiviral agent. |
| Classification | Small molecule |
| Drug class | antivirals: neuraminidase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CC(=O)N[C@@H]1[C@@H](NC(=N)N)C=C(C(=O)O)O[C@H]1[C@H](O)[C@H](O)CO |
Identifiers
| PDB | — |
| CAS-ID | 139110-80-8 |
| RxCUI | 69722 |
| ChEMBL ID | CHEMBL222813 |
| ChEBI ID | 50663 |
| PubChem CID | 60855 |
| DrugBank | DB00558 |
| UNII ID | L6O3XI777I (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 5,653 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
2,821 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more